NMRA:NASDAQNeumora Therapeutics, Inc. analysis
Data as of Sep 15, 2026 - not real-time
- Latest price
- $1.00
- Risk: high
- 9/10High risk
Summary
The moving-average structure behind Neumora Therapeutics, Inc. is bearish at $0.9994, with short-term averages lagging the long-term ones. Over a rolling month the price has lost 38.0%. With RSI at 24.3 the momentum picture is oversold, alongside a bearish MACD signal. Price has been bracketed by support at $0.9900 and resistance at $1.71.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 514.7% above today's level.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 70.2%, a beta of 0.78 and a maximum drawdown of 74.5%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 91 on the fear-greed composite.
Near-term and long-term part ways here — sell short-term against hold longer out, with 3/10 conviction on the long call.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 514.7% above today's level.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 70.2%, a beta of 0.78 and a maximum drawdown of 74.5%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 91 on the fear-greed composite.
Near-term and long-term part ways here — sell short-term against hold longer out, with 3/10 conviction on the long call.
Top market events
- Favorable pre-clinical data reported for NMRA-215 with plan to submit IND in fourth quarter of 2026 and initiate Phase...
- Favorable pre-clinical data reported for NMRA-215 with plan to submit IND in fourth quarter of 2026 and initiate Phase...
- Nasdaq1monNeumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateFavorable...
Market outlook
Short term
< 1 yearCautious
Model confidence4/104 out of 10
Key factors
- Short-term moving averages stacked below long-term ones
- RSI at 24.3 signals oversold conditions
- Trading below the 200-day average of 2.03
Medium term
1–3 yearsCautious
Model confidence4/104 out of 10
Key factors
- Short-term moving averages stacked below long-term ones
- RSI at 24.3 signals oversold conditions
- Trading below the 200-day average of 2.03
Long term
> 3 yearsNeutral
Model confidence3/103 out of 10
Key factors
- Analyst targets imply +514.7% versus the current price
- Negative return on equity of -187.1%
- Negative free cash flow
Key metrics
Financial health
P/E Ratio-1.5
ROE-187.11%
ROA-73.85%
Debt/Equity119.62
P/B Ratio4.2
Op. Cash Flow$-180520000
Free Cash Flow$-99416872
Industry P/E30.0
Technical analysis
TrendBearish
RSI24.3
Support$0.99
Resistance$1.71
MA 20$1.39
MA 50$1.53
MA 200$2.03
MACDBearish
VolumeDecreasing
Fear & Greed Index90.89
Valuation
Target Price$6.14
Upside/Downside514.65%
GradeFair
TypeGrowth
Risk assessment
Beta0.78
Volatility70.16%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.